SMEDDS based Hepaphil boasts of better bioavailability

Published: 2004-02-27 06:57:00

Updated: 2004-02-27 06:57:00

KMS Company said that it has marketed Hepaphil soft capsule (biphenyl dimethyl dicarboxylate; BDD) to improve the dissolution rate of poorly water soluble drug using self-microemulsifying drug delivery system (SMEDDS), which was developed by local researchers of Pharmacy College, Sungkyunkwan Uni...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK